Clinical Trial: A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R08b in Parkinson's Disease Patients With GBA1 Mutations

U.S., Feb. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07414290) titled 'A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R08b in Parkinson's Disease Patients With GBA1 Mutations' on Feb. 09.

Brief Summary: A Phase I/II Clinical Study to Evaluate the Tolerability, Safety, and Efficacy of VGN-R08b Intra-cerebroventricular injection in Parkinson's Disease Patients with GBA1 Mutations

Study Start Date: March 01

Study Type: INTERVENTIONAL

Condition: Parkinson Disease (PD)

Intervention: DRUG: VGN-R08b

This is a Phase I/II trial, with safety as the primary measure. Sample size is not determined through statistical justification. There will be 3 subjects in each dose cohort in the dose esca...